Literature DB >> 12879461

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders.

Anas Younes1, Bharat B Aggarwall.   

Abstract

Tumor necrosis factor (TNF), originally identified as a factor produced in the serum of endotoxin-injected animals, is a cytokine that mediates tumor necrosis. To date, 20 different members of the TNF superfamily and 21 different receptors have been identified. All ligands of the TNF superfamily have been found to activate transcription factor NF-kappaB and c-Jun kinase. Members of this family have diverse biologic effects, including induction of apoptosis, promotion of cell survival, and regulation of the immune system. The current review focuses on four members that play important roles in regulating hematopoietic cells and are involved in the pathogenesis of several hematologic malignancies. The potential therapeutic use of these members also is discussed. Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11524

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879461     DOI: 10.1002/cncr.11524

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  New molecular targets for treatment of lymphoma.

Authors:  Barbara Pro; Anas Younes
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 2.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

Review 3.  Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Authors:  Michelle A Fanale; Anas Younes
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

Authors:  Adam Jona; Anas Younes
Journal:  Blood Rev       Date:  2010-09-15       Impact factor: 8.250

5.  Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.

Authors:  Anneclaire J De Roos; Dana K Mirick; Kerstin L Edlefsen; Andrea Z LaCroix; Kenneth J Kopecky; Margaret M Madeleine; Larry Magpantay; Otoniel Martínez-Maza
Journal:  Cancer Res       Date:  2012-07-30       Impact factor: 12.701

6.  Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.

Authors:  Brenda M Birmann; Elizabeth C Breen; Sherri Stuver; Beverly Cranston; Otoniel Martínez-Maza; Kerstin I Falk; Akihiko Okayama; Barrie Hanchard; Nancy Mueller; Michie Hisada
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

7.  Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

Authors:  Christos Vaklavas; Andres Forero-Torres
Journal:  Ther Adv Hematol       Date:  2012-08

8.  The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-kappaB-dependent transcription.

Authors:  Casey W Wright; Colin S Duckett
Journal:  Science       Date:  2009-01-09       Impact factor: 47.728

9.  TNF-alpha downregulates E-cadherin and sensitizes response to γ-irradiation in Caco-2 cells.

Authors:  Jae Youn Yi; Yu-Jin Jung; Sun Shim Choi; Eunkyung Chung
Journal:  Cancer Res Treat       Date:  2009-09-30       Impact factor: 4.679

10.  TNF-α inhibitors: are they carcinogenic?

Authors:  Girindra Raval; Paulette Mehta
Journal:  Drug Healthc Patient Saf       Date:  2010-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.